Mizuho Maintains Outperform on Assembly Biosciences, Lowers Price Target to $45

Benzinga · 2d ago
Mizuho analyst Salim Syed maintains Assembly Biosciences (NASDAQ:ASMB) with a Outperform and lowers the price target from $53 to $45.